-
pSivida Announces New Safety and Efficacy Data from Phase 3 Study of ILUVIEN® in Diabetic Macular Edema (PSDV)
Tuesday, May 3, 2011 - 9:18am | 123pSivida Corp. (NASDAQ: PSDV), a leader in developing sustained release, drug delivery products for treatment of back-of-the-eye diseases, today announced the presentation of new data from the completed 36-month FAME™ Study of ILUVIEN for the treatment of Diabetic Macular Edema at the 2011 ARVO...
-
Duncan-Williams Maintains Buy on eResearch Technology (ERES)
Tuesday, May 3, 2011 - 8:48am | 117Duncan-Williams is out with its report on eResearch Technology (NASDAQ: ERES), maintaining Buy. In a note to clients, Duncan-Williams writes, "ERT reported Q1:11 revenue and adjusted EPS of $41.7 million and $0.09, below our revenue estimate of $42.5 million and above our adjusted EPS estimate of...
-
Benzinga's Top Pre-Market NASDAQ Losers (PRXL, SWSH, ANAD, CTSH)
Tuesday, May 3, 2011 - 8:20am | 115PAREXEL International Corporation (NASDAQ: PRXL) dipped 20.39% to $21.51 in the pre-market session. PRXL lowered its profit and revenue guidance for fiscal 2011. Swisher Hygiene Inc (NASDAQ: SWSH) fell 8.28% to $7.98 in the pre-market session. SWSH acquired ProClean of Arizona Inc. ANADIGICS Inc...
-
Jefferies Maintains Buy on PAREXEL Int'l (PRXL)
Tuesday, May 3, 2011 - 7:55am | 87Jefferies is out with its report today on PAREXEL Int'l (NASDAQ: PRXL), maintaining Buy. In a note to clients, Jefferies writes, "PAREXEL reported earnings that missed expectations. Management's guidance reduces revenue, but offsets that with higher costs? Share gains continue to drive high...
-
Techne Corporation Announces Acquisition (TECH)
Tuesday, May 3, 2011 - 7:43am | 80Techne Corporation (NASDAQ: TECH) announced today that it has acquired 100% ownership of Tocris Holdings Limited and subsidiaries. Tocris' products are used in both in-vitro and in-vivo experiments, to understand biological processes and diseases. The business is focused on making biologically...
-
Techne Corp Reports EPS of $0.84 vs. $0.80 Estimate; Revenues $76.3M vs. $73.73M Estimate (TECH)
Tuesday, May 3, 2011 - 7:42am | 22Techne Corp (NASDAQ: TECH) Reports EPS of $0.84 vs. $0.80 Estimate; Revenues $76.3M vs. $73.73M Estimate
-
Techne Corporation Releases Third Quarter Results for Fiscal Year 2011
Tuesday, May 3, 2011 - 6:56am | 90Techne Corporation's (NASDAQ: TECH) consolidated pretax net earnings for the quarter ended March 31, 2011 increased 9.5% to $45.4 million compared with $41.4 million for the quarter ended March 31, 2010, mainly as a result of increased sales and foreign exchange transaction gains, partially offset...
-
CEOWORLD TOP 10 Technology Stocks Picks to Watch 5/3/11- ORS, VRNG, HMNA, FEIM, ECTY, GNMK, HRBN, AFFX, CSOD, INVE
Tuesday, May 3, 2011 - 1:06am | 1540Orsus Xelent Technologies Inc. (AMEX:ORS)- Orsus Xelent Technologies, Inc. is an emerging designer and manufacturer of award-winning mobile phones for the Asian market, primarily the People's Republic of China (“PRC”). The Company's business encompasses the design of mobile phones, related...
-
PAREXEL International Corp Resumes Trading (PRXL)
Monday, May 2, 2011 - 4:30pm | 15PAREXEL International Corp (NASDAQ: PRXL) Resumes Trading
-
PREVIEW: PAREXEL International Corp To Resume Trading At 4:30 p.m. EST (PRXL)
Monday, May 2, 2011 - 4:26pm | 21PREVIEW: PAREXEL International Corp (NASDAQ: PRXL) To Resume Trading At 4:30 p.m. EST
-
Parexel International Reports EPS of $0.26 vs. $0.30 Estimate; Revenues $319M vs. $309.29M Estimate (PRXL)
Monday, May 2, 2011 - 4:06pm | 22Parexel International (NASDAQ: PRXL) Reports EPS of $0.26 vs. $0.30 Estimate; Revenues $319M vs. $309.29M Estimate.
-
UPDATE: Genetic Technologies Trading Over 30% Higher Today (GENE)
Monday, May 2, 2011 - 10:05am | 31Genetic Technologies (NASDAQ: GENE) is trading higher today. At the time of posting, shares of GENE were trading at $7.55, up 30.85% from Friday's close.
-
Goldman Sachs Initiates Coverage On Exelixis (EXEL)
Monday, May 2, 2011 - 9:11am | 138Goldman Sachs is initiating coverage on shares of Exelixis (NASDAQ: EXEL) with a Neutral rating and a $13 price target on shares. In a note to investors, Goldman writes, "We are initiating coverage on Exelixis (EXEL) with a Neutral rating and a 12-month price target of $13. The key driver for...
-
SeraCare Life Sciences Announces Renewal of National Institutes of Health Contract to Support Research (SRLS)
Monday, May 2, 2011 - 8:10am | 127SeraCare Life Sciences (NASDAQ: SRLS) announced today that the National Heart, Lung, and Blood Institute of the National Institutes of Health has awarded a new contract to SeraCare, replacing the current contract which expired on April 30, 2011. Under this contract, SeraCare, at the direction of...
-
Goldman Sachs Initiates Coverage On EXEL
Monday, May 2, 2011 - 7:20am | 108Goldman Sachs has initiated coverage on Elexixis Inc. (NASDAQ: EXEL) with a Neutral rating and a price target of $13. Says Goldman Sachs, in its report, “The key driver for shares is Cabo, an oral drug in development for a variety of cancers. We view the prostate cancer opportunity as most...